Nebulized Ensifentrine Shows Promise as Add-on Therapy
Verona Pharma has announced positive efficacy and safety results about using nebulized ensifentrine as an add-on therapy to tiotropium (Spiriva Respimat) for treating symptomatic chronic obstructive pulmonary disease (COPD). Results from the Phase 2b clinical trial (NCT03937479) show that ensifentrine treatment, combined with maintenance tiotropium, results in…